Il y a eu 50 transactions d'initiés récentes enregistrées pour Sensei Biotherapeutics, Inc. (SNSE), dont 30 achats et 14 ventes. Le total des achats d'initiés s'élève à $34.69M et le total des ventes d'initiés à $4.14M.
Les initiés notables ayant une activité récente comprennent Parikh Anand Kiran, Donenberg Phillip B., Cambrian Biopharma Inc. Les transactions d'initiés peuvent fournir des indications sur la façon dont la direction perçoit la valorisation et les perspectives futures de l'action.
Transactions d'Initiés — SNSE
| Date |
Nom |
Rôle |
Type de Transaction |
Actions |
Prix Moyen |
Valeur |
Actions détenues |
| 2026-02-19 |
Parikh Anand Kiran |
Chief Operating Officer |
Attribution de RSU |
1,239,305 |
$27.22 |
$33.73M |
1,239,305 |
| 2026-02-17 |
Parikh Anand Kiran |
Officer |
Inconnu |
- |
- |
- |
- |
| 2026-02-17 |
Parikh Anand Kiran |
Chief Operating Officer |
Attribution de RSU |
56,673 |
$1.16 |
$65.74K |
56,673 |
| 2026-02-13 |
Donenberg Phillip B. |
Officer |
Inconnu |
- |
- |
- |
- |
| 2026-02-13 |
Donenberg Phillip B. |
Director |
Attribution de RSU |
1,900 |
$9.09 |
$17.27K |
1,900 |
| 2025-12-09 |
Cambrian Biopharma Inc |
10 Percent Owner |
Exercice d'Options (Vente) |
395 |
$6.40 |
$2.53K |
- |
| 2025-12-09 |
Peyer James |
10 Percent Owner, Other: See Remarks Below |
Exercice d'Options (Vente) |
395 |
$6.40 |
$2.53K |
- |
| 2025-12-08 |
Peyer James |
10 Percent Owner, Other: See Remarks Below |
Vente Informative |
3,105 |
$8.59 |
$26.67K |
158,254 |
| 2025-12-05 |
Cambrian Biopharma Inc |
10 Percent Owner |
Vente Informative |
42 |
$13.16 |
$552.72 |
161,359 |
| 2025-12-05 |
Peyer James |
10 Percent Owner, Other: See Remarks Below |
Vente Informative |
42 |
$13.16 |
$552.72 |
161,359 |
| 2025-12-04 |
Cambrian Biopharma Inc |
10 Percent Owner |
Vente Informative |
5,000 |
$9.06 |
$45.3K |
177,654 |
| 2025-12-04 |
Peyer James |
10 Percent Owner, Other: See Remarks Below |
Vente Informative |
5,000 |
$9.06 |
$45.3K |
177,654 |
| 2025-11-14 |
Gerry Christopher |
President & Peo |
Inconnu |
5,881 |
$15.70 |
$92.34K |
- |
| 2025-05-21 |
Ricks Thomas G |
Director |
Attribution de RSU |
19,000 |
$0.32 |
$6.08K |
19,000 |
| 2025-05-21 |
Ringo William R |
Director |
Attribution de RSU |
19,000 |
$0.32 |
$6.08K |
19,000 |
| 2025-05-21 |
Cambrian Biopharma Inc |
10 Percent Owner |
Attribution de RSU |
19,000 |
$0.32 |
$6.08K |
19,000 |
| 2025-05-21 |
Holmen Bob |
Director |
Attribution de RSU |
19,000 |
$0.32 |
$6.08K |
19,000 |
| 2025-05-21 |
Peyer James |
10 Percent Owner |
Attribution de RSU |
19,000 |
$0.32 |
$6.08K |
19,000 |
| 2025-05-21 |
Humer Kristian |
Director |
Attribution de RSU |
19,000 |
$0.32 |
$6.08K |
19,000 |
| 2025-02-19 |
Celebi John |
President and CEO |
Retenue Fiscale RSU |
5,558 |
$0.48 |
$2.65K |
105,862 |
| 2025-02-19 |
Van Der Horst Edward |
Chief Scientific Officer |
Retenue Fiscale RSU |
2,276 |
$0.48 |
$1.08K |
59,794 |
| 2025-02-14 |
Celebi John |
President and CEO |
Attribution de RSU |
360,000 |
$0.48 |
$171.36K |
360,000 |
| 2025-02-14 |
Van Der Horst Edward |
Chief Scientific Officer |
Attribution de RSU |
110,000 |
$0.48 |
$52.36K |
110,000 |
| 2025-02-14 |
Krebs Stephanie |
Chief Business Officer |
Attribution de RSU |
120,000 |
$0.48 |
$57.12K |
120,000 |
| 2025-02-14 |
Craver Josiah |
Principal Financial Officer |
Attribution de RSU |
50,000 |
$0.48 |
$23.8K |
50,000 |
| 2024-12-20 |
Celebi John |
President and CEO |
Attribution de RSU |
355,000 |
$0.45 |
$159.71K |
355,000 |
| 2024-12-20 |
Van Der Horst Edward |
Chief Scientific Officer |
Attribution de RSU |
100,000 |
$0.45 |
$44.99K |
100,000 |
| 2024-12-20 |
Krebs Stephanie |
Chief Business Officer |
Attribution de RSU |
120,000 |
$0.45 |
$53.99K |
120,000 |
| 2024-12-20 |
Craver Josiah |
Principal Financial Officer |
Attribution de RSU |
100,000 |
$0.45 |
$44.99K |
100,000 |
| 2024-09-17 |
Craver Josiah |
Principal Financial Officer |
Inconnu |
80,000 |
$0.66 |
$52.8K |
- |
| 2024-06-11 |
Ricks Thomas G |
Director |
Attribution de RSU |
19,000 |
$0.71 |
$13.47K |
19,000 |
| 2024-06-11 |
Ringo William R |
Director |
Attribution de RSU |
19,000 |
$0.71 |
$13.47K |
19,000 |
| 2024-06-11 |
Cambrian Biopharma Inc |
10 Percent Owner |
Attribution de RSU |
19,000 |
$0.71 |
$13.47K |
19,000 |
| 2024-06-11 |
Holmen Bob |
Director |
Attribution de RSU |
19,000 |
$0.71 |
$13.47K |
19,000 |
| 2024-06-11 |
Vojta Deneen |
Director |
Attribution de RSU |
19,000 |
$0.71 |
$13.47K |
19,000 |
| 2024-06-11 |
Peyer James |
10 Percent Owner |
Attribution de RSU |
19,000 |
$0.71 |
$13.47K |
19,000 |
| 2024-06-11 |
English Jessie |
Director |
Attribution de RSU |
19,000 |
$0.71 |
$13.47K |
19,000 |
| 2024-06-11 |
Humer Kristian |
Director |
Attribution de RSU |
19,000 |
$0.71 |
$13.47K |
19,000 |
| 2024-05-10 |
Gaiero David G |
Officer |
Inconnu |
- |
- |
- |
- |
| 2024-02-15 |
Celebi John |
President and CEO |
Retenue Fiscale RSU |
5,891 |
$0.79 |
$4.65K |
105,420 |
| 2024-02-15 |
Colgan Erin |
Chief Financial Officer |
Retenue Fiscale RSU |
3,627 |
$0.79 |
$2.87K |
67,462 |
| 2024-02-15 |
Van Der Horst Edward |
Chief Scientific Officer |
Retenue Fiscale RSU |
2,843 |
$0.79 |
$2.25K |
56,070 |
| 2023-11-01 |
Krebs Stephanie |
Officer |
Inconnu |
- |
- |
- |
- |
| 2023-11-01 |
Krebs Stephanie |
Chief Business Officer |
Attribution de RSU |
125,000 |
$0.82 |
$102.5K |
125,000 |
| 2023-09-11 |
Celebi John |
President and CEO |
Achat Informatif |
500 |
$0.85 |
$425.00 |
111,311 |
| 2023-07-31 |
Cambrian Biopharma Inc |
10 Percent Owner |
Restitution d'Actions |
1,587,302 |
$1.26 |
$2M |
3,653,120 |
| 2023-07-31 |
Peyer James |
10 Percent Owner |
Restitution d'Actions |
1,587,302 |
$1.26 |
$2M |
3,653,120 |
| 2023-07-10 |
Ricks Thomas G |
Director |
Attribution de RSU |
4,466 |
- |
- |
8,932 |
| 2023-07-10 |
Ringo William R |
Director |
Attribution de RSU |
14,550 |
$1.22 |
$17.75K |
14,550 |
| 2023-07-10 |
Broder Samuel |
Director |
Attribution de RSU |
4,466 |
- |
- |
8,932 |
■ Informatif — transaction sur marché ouvert (la plus significative)
■ Non informatif (achat) — récompense, exercice d'option, conversion
■ Non informatif (vente) — retenue fiscale, vente à l'acquisition
■ Neutre — don, fiducie, expiration
Les autres consultent aussi
